Vertex Pharmaceuticals Gains Updated FDA Approval Letter for CASGEVY Gene Therapy in SCD and TDT

A June 15, 2026 approval letter issued by the FDA under STN 125787 signals continued regulatory engagement with Vertex Pharmaceuticals' exagamglogene autotemcel (exa-cel), marketed as CASGEVY, and for ATMP manufacturers tracking CRISPR-based biologics licensing, the update carries operational weight beyond the product label.

CASGEVY holds approval for two indications under separate STNs: treatment of sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT) in patients 12 years and older. STN 125787 covers both conditions; STN 125785, approved January 16, 2024, addresses SCD with recurrent vaso-occlusive crises (VOCs) alongside TDT. The June 2026 letter follows a March 18, 2026 approval letter under the same STN, indicating iterative post-approval correspondence consistent with lifecycle management under a biologics license application.

For QA directors and regulatory affairs leads at advanced therapy manufacturing sites, the layered approval history, spanning December 2023 through June 2026, reflects the compliance overhead typical of autologous cell and gene therapy platforms. Each approval letter can carry revised labeling, manufacturing supplements, or post-marketing commitments that directly affect batch release protocols, comparability studies, and process validation documentation under 21 CFR Part 211 and applicable CGMP expectations for biological products.

The existence of two active STNs for the same tradename also presents a practical challenge for sites managing parallel production streams: label control, version-specific package inserts, and demographic subgroup data referenced in the Clinical Review Memo must be reconciled across both license numbers. The FDA's published demographic subgroup information for exa-cel directs reviewers to Section 1.1 of the Clinical Review Memo, a reference point relevant to any post-approval efficacy or safety reporting obligations.

Plant heads scaling CRISPR-based autologous manufacturing should note that the supporting document package, now spanning multiple approval letters, two Summary Bases for Regulatory Action, and full approval histories for both STNs, represents the evidentiary baseline against which any future manufacturing changes or comparability protocols will be assessed.

The completeness of the post-approval document trail for STN 125787 will serve as a reference standard as regulators and manufacturers work through the next generation of CRISPR-based ATMP submissions.

Source: FDA Center for Biologics Evaluation and Research (CBER) via FDA.gov Vaccines, Blood and Biologics RSS Feed, June 16, 2026.